PUBLIC/PDR

030-13725 4/96

ANCILLA HEALTH CARE

12-23-96

Region III, Licensing Section
Material Licensing Branch
U.S. Nuclear Regulatory Commission
801 Warrenville Road
Lisle, Illinois 60532-4351

Re: Approval notification of authorized user to License #13-17943-01, Ancilla Health Care, Inc., Mishawaka, Indiana, in accordance with CFR 35.13 and 35.14 dated December 2, 1994.

Gentlemen:

This is notification that the Hospital Administration and the Radiation Safety Committee of Ancilla Health Care, Inc. have approved Timothy Scott Smith, M.D. as a user of materials listed in 10 CFR, Part 35.300 based upon NRC approval to use such materials at another medical facility. Enclosed is a copy of License #13-02650-02 (St. Joseph's Medical Center, South Bend, Indiana) on which he is listed as a user of materials listed in 35.300.

If additional information is required, please contact me at (219) 287-4146 or (219) 237-7287.

Yours truly,

John D. Scheu

John D. Scheu, Ph.D.
Radiation Safety Officer

RECEIVED
JAN 08 1997
REGION III

9701290300 961223
PDR ADOCK 03013705
C PDR

ST. JOSEPH COMMUNITY HOSPITAL
215 W. FOURTH ST.
MISHAWAKA, INDIANA 46544
(219) 259-2431

ST. MARY COMMUNITY HOSPITAL
2515 E. JEFFERSON BLVD.
SOUTH BEND, INDIANA 46615
(219) 288-8311

290099

Pm: 1-6-97

JAN 08 1997

NRC FORM 374 (7-94)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 24

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. St. Joseph's Medical Center	In accordance with letter dated October 27, 1996 3. License Number 13-02650-02 is amended in its entirety to read as follows:
2. P. O. Box 1935 801 East Lasalle Street South Bend, IN 46634-1935	4. Expiration Date June 30, 2004
	5. Docket or Reference No. 030-13685

6. Byproduct, Source, and/or Special Nuclear Material		7. Chemical and/or Physical Form		8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A.	Any byproduct material identified in 10 CFR 35.100	A.	Any radiopharmaceutical identified in 10 CFR 35.100	A.	As needed
B.	Any byproduct material identified in 10 CFR 35.200	B.	Any radiopharmaceutical identified in 10 CFR 35.200	B.	As needed
C.	Any byproduct material identified in 10 CFR 35.300	C.	Any radiopharmaceutical identified in 10 CFR 35.300	C.	As needed
D.	Any byproduct material identified in 10 CFR 35.400	D.	Any brachytherapy source identified in 10 CFR 35.400	D.	As needed
E.	Any byproduct material identified in 10 CFR 35.500	E.	Sealed sources identified in 10 CFR 35.500	E.	As needed
F.	Uranium depleted in Uranium-235	F.	Cadmium plated metal	F.	600 pounds
G.	Technetium-99m	G.	Any	G.	As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

A01240255 4pp.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No. 13-02650-02

Docket or Reference Number 030-13685

Amendment No. 24

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400.

E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

F. Shielding in a linear accelerator.

G. For research and development as described in 10 CFR 30.4, limited to animal studies.

CONDITIONS

10. A. Location of Use: 801 East Lasalle Street, South Bend, Indiana.

B. Location of use for material listed in Subitem 6.G.; St. Joseph's Radiation Oncology Center, Suite 100, 707 East Cedar Street, South Bend, Indiana.

11. Radiation Safety Officer: John D. Scheu, Ph.D.

12. Authorized Users:

A. M. Samir Bawab, M.D., for material in 10 CFR 35.100, 35.200, 35.300 (excluding Iodine-131 for the treatment of thyroid carcinoma) and Strontium-90 for treatment of eye diseases and 35.500.

B. Dean L. Cook, M.D., for material in 10 CFR 35.100, 35.200, 35.300, Strontium-90 for treatment of eye diseases, 35.500 and Technetium-99m for animal research studies.

C Frank E. Rabe, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 as iodide for treatment of Thyroid carcinoma), 35.500 and Technetium-99m for animal research studies.

D. John S. Harding, M.D., for material in 10 CFR 35.100, 35.200, 35.300 and 35.500.

E. Douglas S. Kuehn, M.D., for material in 10 CFR 35.100, 35.200 and 35.500.

F. Robert Rust, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 as iodide for treatment of thyroid carcinoma) and 35.500.

G. Victor Jones, II, M.D., for material in 10 CFR 35.100, 35.200 and 35.500.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number: 13-02650-02
Docket or Reference Number: 030-13685
Amendment No. 24

H. Michael McCrea, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 as iodide for treatment of thyroid carcinoma) and 35.500.

I. Brett A. Stephens, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.500 and Technetium-99m for animal research studies.

J. John D. Scheu, Ph.D., for Cesium-137 for survey instrument calibration and Technetium-99m for animal research studies.

K. Toby Mathews, M.D., for material in 10 CFR 35.100, 35.200, 35.300 and 35.500.

L. David Cory, M.D., for material in 10 CFR 35.100, 35.200 and 35.500.

M. David J. Kraus, M.D., for material in 10 CFR 35.400.

N. Guy Kedziora, M.D., for material in 10 CFR 35.400.

O. Timothy Scott Smith, M.D., for material in 10 CFR 35.100, 35.200 and 35.300.

13. Experimental animals administered licensed materials or their products shall not be used for human consumption.

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 19, 1994.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 11/27/96

By James Mullauer
Nuclear Materials Licensing Branch, Region III

DATE: 1-9-97

CORRESPONDENCE CLARIFICATION SHEET

REVIEWER: BJ HOLT

LICENSEE: Ancilla

LICENSE NUMBER: 13-17943-01

The following correspondence has been received from the above licensee and it is not clear what action(s) is(are) required: Please review this correspondence and indicate which of the following applies, and please return to Debbie Hersey, as soon as possible.

☐ Additional Information to Control No. _____.
Process in as a new action, additional information, and no fee required.

☐ Process as new licensing action. Review has already been started on Control No._____ and this information cannot be combined with current in-house action.

☐ Can be combined with Control No. _____. Review has not started.

☐ Appears to be information for the license file - file it.

☐ Licensee is adding Nuclear Pharmacists.

Amendment is necessary _____. Amendment is not necessary _____.
(Information for license file)

☑ Licensee is adding authorized users.

A check is included _____. No check is included ✓.

Amendment is necessary _____. Amendment is not necessary ✓. OBH
(This is a Notification)

☐ Process in as a new licensing action:

A. Amendment _____
B. Renewal _____
C. New License Application_____

☐ Other:_____

Thank You For Your Help!!! 10/16/96